Cerus Corporation — Q2 2023 Form 10-Q Summary
Business Context and Reporting Period
Cerus develops and commercializes the INTERCEPT Blood System for pathogen reduction of blood components, including platelets, plasma and cryoprecipitation products. The red blood cell system remains in development and has not been commercialized. The filing covers the quarter and six months ended June 30, 2023; results are unaudited and presented under U.S. GAAP. Cerus operates in one reportable segment: blood safety.
Key Financial Metrics
| Metric | Q2 2023 | Q2 2022 | Six Months 2023 | Six Months 2022 |
|---|---|---|---|---|
| Total revenue | $47.7 million | $47.6 million | $86.2 million | $90.7 million |
| Product revenue | $38.9 million | $41.0 million | $69.8 million | $78.4 million |
| Government contract revenue | $8.9 million | $6.6 million | $16.4 million | $12.2 million |
| Gross profit on product revenue | $21.3 million | $21.3 million | $38.6 million | $40.6 million |
| Product gross margin | 55% | 52% | 55% | 52% |
| Loss from operations | $(11.6) million | $(6.8) million | $(25.8) million | $(16.7) million |
| Net loss attributable to Cerus | $(13.3) million | $(8.4) million | $(28.9) million | $(20.7) million |
| Loss per share | $(0.07) | $(0.05) | $(0.16) | $(0.12) |
| Cash flow from operations | Not separately disclosed | Not separately disclosed | $(17.5) million | $(21.8) million |
Product revenue declined 5% in the quarter and 11% year to date, primarily because of lower U.S. disposable platelet-system kit volume and, for the six-month period, unfavorable euro translation. Government contract revenue increased 34% in both comparable periods, primarily due to higher BARDA revenue and the DoD contract. Higher R&D spending, SG&A costs, restructuring charges and interest expense drove the wider operating and net losses.
Liquidity, Capital Resources and Debt
- Cash and cash equivalents were $20.6 million at June 30, 2023, compared with $35.6 million at December 31, 2022.
- Short-term investments were $63.9 million versus $66.6 million; restricted cash was $1.8 million. Total cash, investments and restricted cash were $86.3 million, down from $103.9 million.
- Working capital was $75.9 million, compared with $53.1 million at year-end, primarily because $41.5 million of debt was reclassified from current to non-current under the amended term-loan agreement.
- Total debt was $71.4 million, consisting of $54.8 million of non-current term debt and $16.5 million drawn under the revolving facility. The term loan carried an interest rate of approximately 11.8% at June 30, 2023.
- The amended facilities provide for a $75.0 million secured term-loan facility and an initial $20.0 million revolving facility, with potential revolving commitments of up to $35.0 million subject to conditions. The company was in compliance with stated debt covenants at quarter-end.
- Scheduled term-loan principal payments are not shown before 2026; principal repayments are scheduled to begin in 2026 unless the facility is restructured. Interest and fees are expected to total $26.2 million over the scheduled debt term.
- Management believes available liquidity, product receipts and government-contract receipts will meet capital requirements for at least the next 12 months, but acknowledges that this assessment depends on assumptions that may prove incorrect.
Material Changes Versus the Prior Comparable Period
- Total revenue was approximately flat in Q2 but declined 5% for the first six months because of lower product revenue.
- Product gross margin improved to 55% from 52%, benefiting from sales mix, greater U.S. kit sales and favorable currency effects on euro-denominated manufacturing and supply costs.
- R&D expense rose 26% in Q2 and 25% year to date, primarily reflecting development of a next-generation illuminator and increased clinical research activities.
- SG&A expense increased 5% in both periods, driven mainly by legal, commercialization and stock-based compensation costs.
- Interest expense increased 62% in Q2 and 39% year to date because of higher interest rates on the term loan.
- In June 2023, Cerus began a restructuring plan involving a workforce reduction of approximately 10% and facilities consolidation. Q2 restructuring expense was $2.1 million, including $1.7 million of termination benefits. Additional facilities-related charges were expected in Q3.
- The company amended its BARDA agreement in March 2023, increasing committed funding to as much as $182.0 million and extending potential total funding to $278.9 million through September 2026, subject to option exercises, milestones and other conditions.
- The DoD agreement was amended in May 2023, extending it through February 2027 and increasing potential contract value from $9.1 million to $17.8 million.
Guidance, Outlook, Commentary and Risks
- Management expects product revenue growth in future periods, driven by platelet-business growth, increased market acceptance and adoption in additional geographies. The filing does not provide a quantitative revenue or earnings outlook.
- Management expects continuing R&D and commercialization spending, including costs for the red blood cell system, product enhancements, regulatory submissions, clinical studies, the next-generation illuminator and government-contract activities.
- Cerus expects to remain loss-making and may never achieve profitability. The company may require additional debt, equity, government funding or strategic financing; future equity issuance could dilute shareholders.
- BARDA funding is subject to milestones, government appropriations, option exercises and BARDA’s right to terminate for convenience. Failure to obtain additional funding could delay or curtail red blood cell development.
- The red blood cell system remains subject to clinical, manufacturing and regulatory risks, including uncertainty regarding the European CE Certificate of Conformity, FDA requirements and a dispute with a key supplier.
- Cerus relies heavily on third-party manufacturers, including Fresenius as the sole supplier of finished platelet and plasma disposable kits, creating supply, capacity, quality and obsolescence risks. U.S. platelet-kit shelf life remains limited to six months for products using a new solvent until supporting data is accepted by the FDA.
- Customer and market concentration is material: the American Red Cross represented 39% of Q2 product revenue and 36% of six-month product revenue; EFS represented 12% and 13%, respectively.
- The company is responding to a civil investigative demand from the U.S. Department of Justice Antitrust Division concerning contracting and information-exchange practices. No claim or proceeding had been initiated as of the filing date, but the investigation could result in costs, penalties, business-practice changes or adverse publicity.
- As a subsequent event, Cerus committed to cease using part of its Concord office during Q3 and plans to sublease the space. The company expected to assess the related right-of-use asset impact in Q3.
- Other significant risks include regulatory approval and post-market obligations, clinical-trial delays, product liability or recalls, reimbursement and adoption uncertainty, foreign exchange exposure, inflation, cybersecurity, intellectual-property disputes and dependence on concentrated customers and suppliers.
Most Important Facts for Investors to Verify
- Whether U.S. platelet-kit volumes and overall product revenue begin to recover as management expects.
- The sustainability of the 55% product gross margin amid inflation, supply-chain costs, inventory levels and product mix.
- Cash burn, liquidity runway and the company’s ability to fund operations before debt principal amortization begins.
- Compliance with debt covenants and the effect of approximately 11.8% floating-rate debt on future interest expense.
- Progress, funding availability and milestone performance under BARDA and DoD contracts.
- Regulatory progress for the red blood cell system, including resolution of the key-supplier dispute and the timing of any European certification or FDA submission.
- Execution of the restructuring and facilities consolidation plan, including additional charges and operating effects.
- Resolution and potential financial or operational consequences of the DOJ Antitrust Division investigation.
- Fresenius and other suppliers’ ability to expand capacity, maintain quality and address component obsolescence and product shelf-life constraints.